These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31819803)

  • 1. Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms.
    Medina LD; Torres S; Alvarez E; Valdez B; Nair KV
    Mult Scler J Exp Transl Clin; 2019; 5(4):2055217319885986. PubMed ID: 31819803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis.
    Miller DM; Bethoux F; Victorson D; Nowinski CJ; Buono S; Lai JS; Wortman K; Burns JL; Moy C; Cella D
    Mult Scler; 2016 May; 22(6):830-41. PubMed ID: 26238464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis.
    Matza LS; Phillips G; Dewitt B; Stewart KD; Cella D; Feeny D; Hanmer J; Miller DM; Revicki DA
    Med Decis Making; 2020 Oct; 40(7):897-911. PubMed ID: 33016238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy.
    Victorson D; Cavazos JE; Holmes GL; Reder AT; Wojna V; Nowinski C; Miller D; Buono S; Mueller A; Moy C; Cella D
    Epilepsy Behav; 2014 Feb; 31():77-84. PubMed ID: 24361767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between PROMIS10, SF-36 and NeuroQoL in persons with multiple sclerosis.
    Healy BC; Liu Y; Winston-Khan S; Weiner HL; Chitnis T; Glanz BI
    Mult Scler Relat Disord; 2023 Nov; 79():105003. PubMed ID: 37741027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.
    Carlozzi NE; Goodnight S; Kratz AL; Stout JC; McCormack MK; Paulsen JS; Boileau NR; Cella D; Ready RE
    J Huntingtons Dis; 2019; 8(4):467-482. PubMed ID: 31424415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab.
    Hersh CM; Pang M; Miller DM; McGinley MP; Hyland M; Ziemssen T; Avila RL
    Neurodegener Dis Manag; 2024; 14(2):21-33. PubMed ID: 38623894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring Fatigue in Multiple Sclerosis: There may be Trouble Ahead.
    Close J; Vandercappellen J; King M; Hobart J
    Neurol Ther; 2023 Oct; 12(5):1649-1668. PubMed ID: 37353721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing.
    Gershon RC; Lai JS; Bode R; Choi S; Moy C; Bleck T; Miller D; Peterman A; Cella D
    Qual Life Res; 2012 Apr; 21(3):475-86. PubMed ID: 21874314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).
    Carlozzi NE; Schilling SG; Lai JS; Paulsen JS; Hahn EA; Perlmutter JS; Ross CA; Downing NR; Kratz AL; McCormack MK; Nance MA; Quaid KA; Stout JC; Gershon RC; Ready RE; Miner JA; Barton SK; Perlman SL; Rao SM; Frank S; Shoulson I; Marin H; Geschwind MD; Dayalu P; Goodnight SM; Cella D
    Qual Life Res; 2016 Oct; 25(10):2441-2455. PubMed ID: 27522213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining Normative Reference Values and Item-Level Symptom Endorsement for the Quality of Life in Neurological Disorders (Neuro-QoL™) v2.0 Cognitive Function-Short Form.
    Iverson GL; Connors EJ; Marsh J; Terry DP
    Arch Clin Neuropsychol; 2021 Jan; 36(1):126-134. PubMed ID: 32851403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL™) scale.
    Berghöfer P; Fragkos KC; Baxter JP; Forbes A; Joly F; Heinze H; Loth S; Pertkiewicz M; Messing B; Jeppesen PB
    Clin Nutr; 2013 Oct; 32(5):789-96. PubMed ID: 23274148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures.
    Lai JS; Goodnight S; Downing NR; Ready RE; Paulsen JS; Kratz AL; Stout JC; McCormack MK; Cella D; Ross C; Russell J; Carlozzi NE
    Qual Life Res; 2018 Mar; 27(3):811-822. PubMed ID: 29222609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study.
    Pratap A; Grant D; Vegesna A; Tummalacherla M; Cohan S; Deshpande C; Mangravite L; Omberg L
    JMIR Mhealth Uhealth; 2020 Oct; 8(10):e22108. PubMed ID: 33107827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometric Properties of the Spinal Cord Injury-Quality of Life (SCI-QOL) Resilience Short Form in a Sample With Spinal Cord Injury.
    Kuzu D; Kallen MA; Kratz AL
    Arch Phys Med Rehabil; 2024 Jan; 105(1):59-66. PubMed ID: 37865166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD).
    Carlozzi NE; Boileau NR; Paulsen JS; Downing NR; Ready R; Perlmutter JS; Cella D; Chou KL; McCormack MK; Barton S; Lai JS
    Qual Life Res; 2020 May; 29(5):1393-1403. PubMed ID: 31853881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric Properties of a Generic, Patient-Centred Palliative Care Outcome Measure of Symptom Burden for People with Progressive Long Term Neurological Conditions.
    Gao W; Crosby V; Wilcock A; Burman R; Silber E; Hepgul N; Chaudhuri KR; Higginson IJ;
    PLoS One; 2016; 11(10):e0165379. PubMed ID: 27780237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD).
    Carlozzi NE; Boileau NR; Roché MW; Ready RE; Perlmutter JS; Chou KL; Barton SK; McCormack MK; Stout JC; Cella D; Miner JA; Paulsen JS
    Qual Life Res; 2020 Dec; 29(12):3419-3439. PubMed ID: 32813263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the psychometric properties of generic utility measures in multiple sclerosis.
    Kuspinar A; Mayo NE
    Pharmacoeconomics; 2014 Aug; 32(8):759-73. PubMed ID: 24846760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychometric validation of the celiac disease-specific quality of life survey (CD-QOL) in adults with celiac disease in the United States.
    Dochat C; Afari N; Arigo D
    Qual Life Res; 2023 Aug; 32(8):2195-2208. PubMed ID: 36928648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.